<DOC>
	<DOCNO>NCT01779271</DOCNO>
	<brief_summary>Multi-center , Randomized , Double blind , Controlled Parallel-group Comparative Phase 3 Clinical trial ass efficacy safety Pelubiprofen Compared Loxoprofen patient Acute upper respiratory infection .</brief_summary>
	<brief_title>Phase 3 Study Pelubiprofen &amp; Loxoprofen Patients With Upper Respiratory Tract Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Loxoprofen</mesh_term>
	<criteria>1 . Over 15 year old 2 . Male Female 3 . Patients fever 38.0Â°C due cold ( acute upper respiratory tract infection ) 4 . Patients upper respiratory tract infection outbreak within 2 day receive drug administration 5 . Subjects voluntarily legal guardian agree write consent 1 . Fever reducer administration Within 4 hour screen point 2 . Any incidence febrile crisis past six month 3 . Patients Ulcers , gastrointestinal disorder confirm endoscopy 4 . Patients continuously administrate gastrointestinal disorder relate drug 5 . Patients severe blood damage 6 . Severe hepatic impairment ( ALT , AST value 2 time upper limit normal range ) 7 . With severe renal impairment ( serum creatinine value 2 time upper limit normal range ) 8 . Patients severe leave ventricular dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pelubi</keyword>
	<keyword>Pelubiprofen</keyword>
	<keyword>Loxoprofen</keyword>
	<keyword>Anti-pyretic</keyword>
	<keyword>Fever</keyword>
</DOC>